PIP5K1α is Required for Promoting Tumor Progression in Castration-Resistant Prostate Cancer.
androgen receptor (AR)
castration-resistant prostate cancer (CRPC)
cyclin-dependent kinase (CDK)
matrix metalloproteinases 9 (MMP9) PIP5K1α
phosphatidylinositol 4-phosphate 5 kinase (PIP5K1α)
targeted therapy
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2022
2022
Historique:
received:
20
10
2021
accepted:
11
02
2022
entrez:
7
4
2022
pubmed:
8
4
2022
medline:
8
4
2022
Statut:
epublish
Résumé
PIP5K1α has emerged as a promising drug target for the treatment of castration-resistant prostate cancer (CRPC), as it acts upstream of the PI3K/AKT signaling pathway to promote prostate cancer (PCa) growth, survival and invasion. However, little is known of the molecular actions of PIP5K1α in this process. Here, we show that siRNA-mediated knockdown of PIP5K1α and blockade of PIP5K1α action using its small molecule inhibitor ISA-2011B suppress growth and invasion of CRPC cells. We demonstrate that targeted deletion of the N-terminal domain of PIP5K1α in CRPC cells results in reduced growth and migratory ability of cancer cells. Further, the xenograft tumors lacking the N-terminal domain of PIP5K1α exhibited reduced tumor growth and aggressiveness in xenograft mice as compared to that of controls. The N-terminal domain of PIP5K1α is required for regulation of mRNA expression and protein stability of PIP5K1α. This suggests that the expression and oncogenic activity of PIP5K1α are in part dependent on its N-terminal domain. We further show that PIP5K1α acts as an upstream regulator of the androgen receptor (AR) and AR target genes including CDK1 and MMP9 that are key factors promoting growth, survival and invasion of PCa cells. ISA-2011B exhibited a significant inhibitory effect on AR target genes including CDK1 and MMP9 in CRPC cells with wild-type PIP5K1α and in CRPC cells lacking the N-terminal domain of PIP5K1α. These results indicate that the growth of PIP5K1α-dependent tumors is in part dependent on the integrity of the N-terminal sequence of this kinase. Our study identifies a novel functional mechanism involving PIP5K1α, confirming that PIP5K1α is an intriguing target for cancer treatment, especially for treatment of CRPC.
Identifiants
pubmed: 35386201
doi: 10.3389/fcell.2022.798590
pii: 798590
pmc: PMC8979106
doi:
Types de publication
Journal Article
Langues
eng
Pagination
798590Informations de copyright
Copyright © 2022 Wang, Sarwar, Whitchurch, Collins, Green, Semenas, Ali, Roberts, Morris, Hubert, Chen, El-Schich, Wingren, Grundström, Lundmark, Mongan, Gunhaga, Heery and Persson.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Oncogene. 2019 Jan;38(3):375-389
pubmed: 30104711
Sci Rep. 2020 Jun 26;10(1):10472
pubmed: 32591581
J Cell Sci. 2009 Nov 1;122(Pt 21):3837-50
pubmed: 19889969
Nat Rev Clin Oncol. 2018 May;15(5):273-291
pubmed: 29508857
Mol Med. 2018 Jun 27;24(1):34
pubmed: 30134822
Cell. 2018 Jul 12;174(2):422-432.e13
pubmed: 29909987
Proc Natl Acad Sci U S A. 2006 Oct 24;103(43):15969-74
pubmed: 17043241
Int J Cancer. 2020 Mar 15;146(6):1686-1699
pubmed: 31381135
J Immunol. 2008 Nov 15;181(10):6882-8
pubmed: 18981107
Nature. 2006 May 25;441(7092):424-30
pubmed: 16724053
J Biol Chem. 1996 Dec 20;271(51):32937-43
pubmed: 8955136
Nat Rev Cancer. 2006 Mar;6(3):227-39
pubmed: 16498445
Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):12578-9
pubmed: 25118275
Cancers (Basel). 2020 Sep 22;12(9):
pubmed: 32971916
Cell. 2000 Oct 27;103(3):481-90
pubmed: 11081634
J Clin Invest. 2004 Sep;114(5):623-33
pubmed: 15343380
Int J Cancer. 1978 Mar 15;21(3):274-81
pubmed: 631930
Nat Rev Immunol. 2013 Sep;13(9):649-65
pubmed: 23969736
Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):E3689-98
pubmed: 25071204
Urol Oncol. 2018 Jun;36(6):272-282
pubmed: 29650324
Oncotarget. 2016 Sep 27;7(39):63065-63081
pubmed: 27588408
Nat Rev Drug Discov. 2014 Oct;13(10):723
pubmed: 25270953
Drug Des Devel Ther. 2013 Aug 27;7:875-81
pubmed: 24009414
Nat Commun. 2015 Sep 14;6:8205
pubmed: 26365782
Nat Cancer. 2020 Nov;1(11):1041-1053
pubmed: 34258585
Curr Drug Targets. 2012 Sep 1;13(10):1308-23
pubmed: 22746994
Dev Neurobiol. 2014 Jun;74(6):643-56
pubmed: 24376126
Nat Rev Cancer. 2001 Oct;1(1):34-45
pubmed: 11900250
Cell. 2018 Jul 12;174(2):433-447.e19
pubmed: 29909985